Depression Consultant Better treatment through informed communication

  • Skip to content
  • Jump to main navigation and login

Nav view search

Navigation

Search

You are here: Home Science and Individualizing the Treatment of Depression

Main Menu

  • Home
    • Science and Individualizing the Treatment of Depression
    • Psychiatric Research and the Targeted Treatment of Depression
    • Depressing Medical Mistakes
    • Clinical Wisdom Versus Evidence-Based Treatment
    • Taking the Measure of Depression
    • Bad Messages About Good Treatments
    • Improving the Diagnosis of Depression
    • Trapped at the End of the Second Act
    • Adverse Responders and Antidepressant Effectiveness
    • The Antidepressant Debate
    • Empowering the Depressed Patient
    • Review on Antidepressants and Comment published by New York Times
    • Misinformation about Antidepressants on the Internet
    • How does the Clinaptica app work in practice?
    • What About Bipolar Disorder?
    • The Unfriending of Serotonin
    • What "60 Minutes" Didn't Say About Antidepressants
    • How to Personalize the Treatment of Depression
    • Neuroplastic Man Untangled
    • Throwing Away the PITS
    • A Few of Our Current Patients
    • Around the World
    • Researcher-Clinician Synergy
    • A Welcome to Health Professionals
    • A Welcome to Non-Health Professionals
    • Video: Introducing Clinaptica
    • Press
  • Instructions for Clinaptica Depression Consultant App
  • Antidepressants
  • Additional Self-rating scales
  • Developer Info
  • Research for Professionals
  • Contact

Login Form

Register at no cost to use all the unique resources of this website. Your privacy and confidentiality will be fully respected. If you have already registered, please login.

  • Forgot your password?
  • Forgot your username?
  • Create an account

Thank you for visiting this website. We value your participation and feedback.

Science and Individualizing the Treatment of Depression

  • Print
  • Email

Dr. Richard Metzner writes about the role of neurochemistry in selecting antidepressants for individual patients in the September 2013 issue of ACS Chemical Neuroscience.

 From the article:

"Despite marked differences in the psychobiological profiles of depressed patients, clinical research has not supported selection of antidepressant (AD) medications based on neurochemistry. Prescribers have been advised to start all patients on the same class of ADs and then switch or combine them until benefit is achieved. New research may transform this practice. By matching clinical moderators to neurochemical mediators, health professionals may finally be able to overcome the disappointing remission rates associated with initial AD treatments and avoid the progressively worsening results associated with current trial and error approaches." Metzner RJ (2013) The impact of neurochemical mediators on antidepressant effectiveness, ACS Chem. Neurosci., 2013, 4 (9), pp 1245–1248.

Powered by Joomla!®